The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, months before they were abruptly fired by U.S. Health Secretary Robert F ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report.

In June, infectious disease physicians sounded the alarm over the Trump administration overstepping existing, transparent processes for changing vaccine recommendations, particularly pointing to new ...

Key Takeaways High-risk adults as young as 50 are now eligible for the RSV vaccineThe update follows advice from now-deposed ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...